All In Biotech

Drug Trial Radar · NCT06206174

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies

Last checked: Nov 20, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Feb 28, 2025

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Institute of Hematology & Blood Diseases Hospital, China
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.

Conditions

  • Hematologic Malignancy
  • Non Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia, Adult
  • Myelodysplastic Syndromes

Interventions

  • TGRX-814Drug

    Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal tolerated dose (MTD)Time frame: At end of dose escalation when the probability of DLT of a dose level is greater than 0.359
  2. Recommended phase II dose (RP2D)Time frame: At completion of the dose escalation study, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.